Get the Stockscreener App
4.295
0.00%
0.00501
Adverum Biotechnologies Inc stock is traded at $4.295, with a volume of 108.06K.
It is up +0.00% in the last 24 hours and down -20.22% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$4.30
Open:
$4.24
24h Volume:
108.06K
Relative Volume:
0.20
Market Cap:
$90.13M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.7146
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
+1.42%
1M Performance:
-20.22%
6M Performance:
+23.21%
1Y Performance:
-41.97%
1-Day Range:
$4.24
$4.325
1-Week Range:
$4.14
$4.34
52-Week Range:
$1.78
$8.18
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.295 | 94.59M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.98 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.24 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.45 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.60 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Will Adverum Biotechnologies Inc. stock deliver consistent dividends2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com
Detecting price anomalies in Adverum Biotechnologies Inc. with AIJuly 2025 PreEarnings & Growth-Oriented Investment Plans - newser.com
Chart overlay techniques for tracking Adverum Biotechnologies Inc.Weekly Market Summary & Weekly High Potential Stock Alerts - newser.com
Will Adverum Biotechnologies Inc. (AVU0) stock benefit from mergersInflation Watch & Verified Stock Trade Ideas - newser.com
Volume spikes in Adverum Biotechnologies Inc. stock – what they meanWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com
What the charts say about Adverum Biotechnologies Inc. today2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com
Is Adverum Biotechnologies Inc. stock attractive for growth ETFsPortfolio Performance Summary & Expert Verified Movement Alerts - newser.com
How rising interest rates impact Adverum Biotechnologies Inc. stockQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
Real time social sentiment graph for Adverum Biotechnologies Inc.Recession Risk & AI Optimized Trade Strategies - newser.com
How interest rate cuts could boost Adverum Biotechnologies Inc. stockPortfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Is Adverum Biotechnologies Inc. stock poised for growthWeekly Profit Summary & Weekly High Potential Stock Alerts - newser.com
Eli Lilly To Acquire Adverum Biotechnologies - MSN
Is it too late to sell Adverum Biotechnologies Inc.July 2025 Setups & Fast Entry Momentum Trade Alerts - newser.com
RBC Capital Maintains Adverum Biotechnologies (ADVM) Sector Perform Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
What drives Adverum Biotechnologies Inc AVU0 stock priceEarnings Revision Updates & Free Grow Wealth With Picks - earlytimes.in
RBC Raises Price Target on Adverum Biotechnologies to $4 From $3, Keeps Sector Perform, Speculative Risk - MarketScreener
Adverum Biotechnologies (NASDAQ:ADVM) Stock Rating Lowered by Chardan Capital - MarketBeat
With Adverum Biotechnologies Stock Down 6.0% In A Month, How Confident Are You? - Trefis
How Adverum Biotechnologies Inc. (AVU0) stock responds to bond marketMarket Growth Report & Free Community Consensus Stock Picks - fcp.pa.gov.br
With Adverum, Eli Lilly Made A Small Bet That Could Pay Off Big (NYSE:LLY) - Seeking Alpha
Eli Lilly Taps Eyecare Market With Definitive Agreement to Acquire Adverum Biotechnologies - VisionMonday.com
Lilly To Acquire Californian Gene Therapy Company - InkFreeNews.com
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Sahm
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders - The AI Journal
Lilly Agrees to Acquire Adverum Biotechnologies - Contract Pharma
Eli Lilly to Acquire Adverum Biotechnologies to Advance Gene Therapy for Wet AMD - Digital Health News
Eli Lilly buys Adverum in eye disease gene therapy punt - Pharmaceutical Technology
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):